Ac Immune Stock Analysis

ACIU Stock Analysis Notes

About 38.0% of the company shares are held by company insiders. The book value of AC Immune was presently reported as 0.79. The company recorded a loss per share of 0.92. AC Immune had not issued any dividends in recent years. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. For more info on AC Immune please contact Andrea Pfeifer at 41 21 345 91 21 or go to https://www.acimmune.com.

AC Immune Investment Alerts

ACIU Largest EPS Surprises

View All Earnings Estimates

AC Immune Environmental, Social, and Governance (ESG) Scores

ACIU Stock Institutional Investors

Note, although AC Immune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ACIU Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 336 M.

ACIU Profitablity

Management Efficiency

AC Immune has return on total asset (ROA) of (0.2197) % which means that it has lost $0.2197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7463) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2026. Return On Capital Employed is likely to drop to -0.38 in 2026. At this time, AC Immune's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 21.5 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 183.9 M in 2026.

Technical Drivers

As of the 5th of February, AC Immune owns the Information Ratio of (0.03), variance of 22.73, and Market Risk Adjusted Performance of (0.60). AC Immune technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.

AC Immune Price Movement Analysis

AC Immune Outstanding Bonds

AC Immune Predictive Daily Indicators

AC Immune Forecast Models

AC Immune's time-series forecasting models are one of many AC Immune's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AC Immune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

AC Immune Bond Ratings

AC Immune financial ratings play a critical role in determining how much AC Immune have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for AC Immune's borrowing costs.

AC Immune Debt to Cash Allocation

AC Immune currently holds 5.43 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. AC Immune has a current ratio of 13.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AC Immune's use of debt, we should always consider it together with its cash and equity.

AC Immune Total Assets Over Time

AC Immune Assets Financed by Debt

The debt-to-assets ratio shows the degree to which AC Immune uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

AC Immune Debt Ratio

2.22

It appears most of the AC Immune's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the AC Immune's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of AC Immune, which in turn will lower the firm's financial flexibility.

AC Immune Corporate Bonds Issued

ACIU Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how AC Immune prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ACIU shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AC Immune. By using and applying ACIU Stock analysis, traders can create a robust methodology for identifying ACIU entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ACIU analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ACIU analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

AC Immune stock analysis indicators help investors evaluate how AC Immune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AC Immune shares will generate the highest return on investment. By understating and applying AC Immune stock analysis, traders can identify AC Immune position entry and exit signals to maximize returns.

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.